For example, for melanoma, one of the cancer types with the highest probability of sensitivity to ICIs, 60–70% of patients cannot achieve a clinical benefit from anti-PD-1 treatment; among those that do, 20–30% ultimately experience tumor progression (4). Here, PDCD1 is linked to melanoma.